
Cantargia: Rasonque Approval Clears the Path to Phase Ib for Nadunolimab

Redeye's analyst published a Research Note on Cantargia.

[Click here to read the article](#)

Make sure to add Cantargia to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.

About Redeye Nordic Growth AB

This is a press release from Redeye Nordic Growth AB, a equity research firm specializing in Nordic growth companies within Tech and Life Science. Redeye Nordic Growth is a part of the Redeye group, which also offers services within corporate finance advisory and fund management. <https://services.redeye.se/>

Attachments

[Cantargia: Rasonque Approval Clears the Path to Phase Ib for Nadunolimab](#)